Matches in Nanopublications for { ?s ?p "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP134150.RAvv1xVuDt-rZ5Sm092O1Z6JrJaCxmfFymNqQrdEMJZaE130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP134150.RAvv1xVuDt-rZ5Sm092O1Z6JrJaCxmfFymNqQrdEMJZaE130_provenance.
- NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404063.RAVGemhZT6IhKbAOkFxrC9OVU5ZQlqgB7F7OP3Xntl1GM130_provenance.
- NP126477.RAuCT4szgi141O5_kd7wERyHSpUUpPUl2aVwTgbxfQvzs130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126477.RAuCT4szgi141O5_kd7wERyHSpUUpPUl2aVwTgbxfQvzs130_provenance.
- assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP210558.RABFRNq3OdPER2IbgsVY9vNMasUhmBtSeg2neSi6SsxGc130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP210558.RABFRNq3OdPER2IbgsVY9vNMasUhmBtSeg2neSi6SsxGc130_provenance.
- NP197307.RA79oh42rf6hpINcx7-W86UwRwKkn1AnCQRcbQGUyUiRU130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP197307.RA79oh42rf6hpINcx7-W86UwRwKkn1AnCQRcbQGUyUiRU130_provenance.
- NP492141.RAo4hhQQduTwy4BTlKlWf7vE29xpApKQjY7tHFngTieRs130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492141.RAo4hhQQduTwy4BTlKlWf7vE29xpApKQjY7tHFngTieRs130_provenance.
- NP189658.RA2hMz9WWq_tRGWNm2JuRnx4zlOZ0YOYyiX8HGgBw9iP0130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP189658.RA2hMz9WWq_tRGWNm2JuRnx4zlOZ0YOYyiX8HGgBw9iP0130_provenance.
- NP492134.RAJKIN3EBp7SP8FWPf_X0SoSEuWcMV_Lq2PBsO6OBkVtA130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492134.RAJKIN3EBp7SP8FWPf_X0SoSEuWcMV_Lq2PBsO6OBkVtA130_provenance.
- NP492142.RA0eP-q75k5fd-EEwB47yP2qk7NSDcqR9PdKv8_Tjctw4130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492142.RA0eP-q75k5fd-EEwB47yP2qk7NSDcqR9PdKv8_Tjctw4130_provenance.
- NP210560.RA_Qx6W3jZOCC0_xQAm__zYd0cujncy4QL6SeXBNj0DqU130_assertion description "[The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP210560.RA_Qx6W3jZOCC0_xQAm__zYd0cujncy4QL6SeXBNj0DqU130_provenance.